86,640 Shares in Rezolute, Inc. (NASDAQ:RZLT) Acquired by Man Group plc

Man Group plc purchased a new stake in Rezolute, Inc. (NASDAQ:RZLT - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 86,640 shares of the company's stock, valued at approximately $425,000. Man Group plc owned 0.15% of Rezolute at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the company. JPMorgan Chase & Co. bought a new stake in shares of Rezolute during the 3rd quarter worth $42,000. Alpine Global Management LLC bought a new stake in Rezolute in the fourth quarter worth $54,000. Charles Schwab Investment Management Inc. lifted its stake in Rezolute by 65.4% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 22,757 shares of the company's stock worth $112,000 after purchasing an additional 9,000 shares during the last quarter. Oxford Asset Management LLP bought a new stake in Rezolute in the fourth quarter worth $154,000. Finally, Balyasny Asset Management L.P. bought a new stake in Rezolute in the fourth quarter worth $168,000. 82.97% of the stock is owned by institutional investors.

Insider Buying and Selling at Rezolute

In other news, CEO Nevan C. Elam purchased 12,302 shares of the business's stock in a transaction dated Thursday, March 27th. The shares were purchased at an average price of $2.85 per share, for a total transaction of $35,060.70. Following the completion of the acquisition, the chief executive officer now directly owns 224,119 shares in the company, valued at $638,739.15. This represents a 5.81% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Daron Evans purchased 10,000 shares of the business's stock in a transaction dated Wednesday, March 26th. The shares were purchased at an average price of $2.89 per share, for a total transaction of $28,900.00. Following the acquisition, the chief financial officer now owns 237,900 shares of the company's stock, valued at approximately $687,531. The trade was a 4.39% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders acquired 29,060 shares of company stock valued at $83,694. Corporate insiders own 18.39% of the company's stock.

Rezolute Price Performance

RZLT stock traded up $0.21 during trading on Thursday, reaching $4.16. The company had a trading volume of 898,807 shares, compared to its average volume of 591,527. Rezolute, Inc. has a 52 week low of $2.22 and a 52 week high of $6.19. The company has a market cap of $355.76 million, a P/E ratio of -3.41 and a beta of 1.01. The business has a 50 day moving average of $3.31 and a 200 day moving average of $4.22.

Rezolute (NASDAQ:RZLT - Get Free Report) last announced its earnings results on Tuesday, May 13th. The company reported ($0.27) earnings per share for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.05). Research analysts expect that Rezolute, Inc. will post -0.93 earnings per share for the current year.

Analyst Ratings Changes

Several research firms have weighed in on RZLT. Guggenheim reissued a "buy" rating on shares of Rezolute in a research note on Monday, February 10th. Wedbush reissued an "outperform" rating and issued a $12.00 price target on shares of Rezolute in a research note on Wednesday, May 14th. Wall Street Zen downgraded shares of Rezolute from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd. JMP Securities upped their price objective on shares of Rezolute from $8.00 to $9.00 and gave the company a "market outperform" rating in a research note on Thursday, February 13th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $14.00 price objective on shares of Rezolute in a research note on Monday, April 28th. One research analyst has rated the stock with a sell rating, six have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Rezolute has an average rating of "Moderate Buy" and an average target price of $12.14.

Rezolute Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.